Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
5 clinical trials · Condition
◉ Watch Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
| Record | Firm | Date |
|---|---|---|
| Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia (NCT02689440) | M.D. Anderson Cancer Center | 2016-02-19 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML (NCT02311998) | M.D. Anderson Cancer Center | 2015-04-16 |
| Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors (NCT01751425) | M.D. Anderson Cancer Center | 2013-07-24 |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib (NCT01746836) | M.D. Anderson Cancer Center | 2013-01-17 |
| Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (NCT00254423) | M.D. Anderson Cancer Center | 2005-11-08 |
Track Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.